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temic embolism based on blinded event assessment and intention-to-treat.
Results: During 4268 patient-years (mean 18 months), 96 primary events occurred. The
mean INR in the warfarin group (2.5±0.7) was within target range for 67% of follow-up.
The primary event rate was 2.27%/year with warfarin and 2.23%/year with ximelagatran,
relative risk reduction (RRR) 2% (95% CI –46%, 34%; p = NS). 66% of patients in the
warfarin arm and 69% in the ximelagatran arm completed the trial on assigned treatment.
On-treatment event rates were 2.09%/year and 1.82%/year in the warfarin and ximela-
gatran arms, respectively, RRR 13% (95% CI –38%, 45%; p = NS). Rates of disabling or
fatal stroke, mortality, and major bleeding were similar in both groups. Combined minor
and major hemorrhages were lower with ximelagatran than warfarin (40.0%/year vs
45.0%/year; RRR 11%, 95% CI 2%, 18%; p = 0.014). Within the first 6 months, serum
alanine aminotransferase levels rose >3 times the upper limit of normal in 29 patients on
warfarin (0.8%) vs 224 patients on ximelagatran (6.1%), but returned towards normal in
all cases.
Conclusion: In elderly, high-risk patients with AF, oral ximelagatran without coagulation
monitoring or dose adjustment was at least as effective for prevention of stroke and sys-
temic embolism, and associated with less bleeding than well-controlled warfarin.
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Jonathan L. Halperin, for the Executive Steering Committee on Behalf ofthe SPORTIF 
Investigators, Mount Sinai Medical Center, New York, NY, City Hospital, Lund, Sweden
Background: Nonvalvular atrial fibrillation (AF) affects women less often than men, but
the risk of stroke is greater among women. Warfarin protects against stroke, but is asso-
ciated with bleeding, which occurs more often in women than in men. The oral direct
thrombin inhibitor, ximelagatran (ExantaTM, AstraZeneca), is a potential alternative anti-
coagulant to warfarin.
Methods: The SPORTIF III (open-label, n = 3410) and V (double-blind, n = 3922) noninfe-
riority trials included 2257 women with AF and at least 1 stroke risk factor randomized to
adjusted-dose warfarin (target INR 2.0–3.0) or fixed-dose ximelagatran (36 mg twice
daily). The mean age of female participants (73.4±8.0 years) was similar to that of the
5072 males (69.9±9.1 years). The primary endpoint was stroke (ischemic or hemor-
rhagic) and systemic embolism based on blinded assessment and intention-to-treat.
Results: During 11,233 patient-years (mean 19 months) exposure (3468 in women and
7765 in men) 72 primary events occurred in women and 112 in men. The mean INR with
warfarin (2.5±0.7) was within target range for 67% of follow-up for both genders. In
women, the primary event rate was 2.0%/year with warfarin and 2.2%/year with ximela-
gatran, relative risk reduction (RRR) –10% (95% CI –73%, 31%; p = NS); rates in men
were 1.5%/year and 1.4%/year (RRR 9.0%, 95% CI –32%, 37%; p = NS). On-treatment
event rates were 1.8%/year and 1.5%/year among women in the warfarin and ximelagat-
ran groups (RRR 16%, 95% CI –46%, 52%; p = NS) compared with 1.5%/year and 1.4%/
year among men (RRR 5%, 95% CI -40%, 36%; p = NS). Combined rates of minor and
major hemorrhages were greater among women (42.6%/year vs 36.9%/year on warfarin
and 33.8%/year vs 30.8%/year on ximelagatran; treatment difference in women:
p<0.0001). Within the first 6 months, serum alanine aminotransferase levels rose >3
times the upper limit of normal in 29 patients on warfarin (0.8%) vs 224 patients on ximel-
agatran (6.1%), but returned towards normal in all cases.
Conclusion: In both women and men with AF, oral ximelagatran without coagulation mon-
itoring or dose-adjustment was at least as effective as well-controlled warfarin for preven-
tion of thromboembolism, and was associated with less bleeding.
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Background ACE-inhibitors have shown to reduce albuminuria and cardiovascular
events in patients with hypertension. Our objective was to investigate whether the effect
of fosinopril on cardiovascular events differs between subjects with high or low urinary
albumin excretion (UAE).
Methods Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a
double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864).
Subjects were randomized to fosinopril 20mg or matching placebo. Key entry criteria
were persistent microalbuminuria (15-300mg/24h) and no hypertension (<160/
100mmHg). UAE was measured in 2x24 hour urine collection. UAE was dichotomized
(low: first 4 quintiles, UAE < 50 mg/24h, high: upper quintiles, UAE > 50mg/24h).
Results Mean age was 51.3 ± 11.8 years, 65% was male, mean cholesterol was 223 mg/
dl, mean systolic blood pressure was 130 mmHg and mean diastolic blood pressure was
76 mmHg. During a mean follow-up period of 46.2 ± 7.0 months, 42 (4.9%) cardiovascu-
lar events occurred. The figure below shows the Cox regression analysis divided by UAE
and treatment. In the subjects with low UAE (group A), fosinopril reduced the events from
4.8 % to 3.0 % (relative risk reduction 37.5%). In the subjects with high UAE (group B),
fosinopril reduced the events from 13.0% to 5.3%, a relative risk reduction of 59.2%.
Conclusion Fosinopril reduces cardiovascular events to a greater extent in patients with
albumin excretion above 50 mg/24h.
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Background ACE-inhibitors and HMG-CoA reductase inhibitors have shown to reduce
the progression of intima-media-thickness (IMT) in patient populations with hypertension
or hypercholesterolemia. PREVEND-IT investigated the effect of fosinopril and pravasta-
tin on IMT in non-hypertensive, non-hypercholesterolemic microalbuminuric subjects.
Methods Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a
double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864).
Subjects were randomized to pravastatin 40 mg or matching placebo and to fosinopril
20mg or matching placebo. Key entry criteria were persistent microalbuminuria (15-
300mg/24h), no hypertension (<160/100mmHg) and no hypercholesterolemia (<308 mg/
dl). Microalbuminuria was measured in 2x24 hour urine collection. The IMT was mea-
sured at the posterior wall of the left common carotid artery using radio frequency signal
analysis obtained by M-mode ultra-sonography.
Results Mean age was 50.8 ± 11.4 years and 65% was male. The table below shows the
median IMT at baseline and after 4 years of follow-up divided by the different strategies.
These median IMT values are within the range of normal values found in our laboratory.
Conclusion Neither fosinopril and pravastatin showed an effect on the carotid IMT after
4 years of follow-up. The normal IMT values found in this population suggests that
microalbuminuria is an early risk indicator already present before detectable vascular
changes.
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825-5 Long-Term Bosentan Improves the Quality of Life of 
Patients With Pulmonary Arterial Hypertension
Adaani Frost, The BREATHE-1 Study Group, Baylor College of Medicine and the 
Methodist Hospital, Houston, TX
Background: Bosentan is an oral endothelin receptor antagonist that improves hemody-
namics and delays the time to clinical worsening in patients with pulmonary arterial
hypertension (PAH). In the BREATHE-1 study, the effect of long-term bosentan treatment
on the well being of PAH patients was investigated.
Methods: 213 patients with PAH (primary or associated with scleroderma) in WHO func-
tional class III or IV were enrolled in a double-blind, placebo-controlled study for 16
weeks (2:1 bosentan:placebo). Of these patients, 48 (35 bosentan; 13 placebo) contin-
ued double-blind study medication for up to 28 weeks (median exposure 26.9 weeks for
bosentan, 26.3 weeks for placebo). Patients received bosentan (62.5 mg bid for 4 weeks
then 125 or 250 mg bid) or placebo. Efficacy endpoints included the 6-minute walk dis-
tance, Borg dyspnea index and WHO functional class.
Results: Bosentan significantly improved the 6-minute-walk distance at Week 16 (+36 ±
6 m, mean ± sem) compared to placebo (-8 ± 12 m), (p < 0.001, n = 213), and the
improvement was maintained for up to 28 weeks (bosentan: +43 ± 14 m; placebo +6 ± 21
m, n = 48). In parallel, the Borg dyspnea index was decreased with bosentan and
increased with placebo resulting in a mean treatment effect of -0.6 (CI: [-1.2 -0.1]) at
week 16 (p =0.05, n =213) which was maintained (-0.8; CI: [-2.0 +0.3], n = 48) for up to
28 weeks. At Week 16, more patients on bosentan than on placebo showed an improve-
ment in WHO functional class (42.4% versus 30.4%, p = 0.04, n = 213). In the 48 patients
studied up to week 28, there was no significant difference in percentage of patients with
improvement over baseline in WHO class between the bosentan and placebo groups
Effect of treatment on IMT (mm), expressed as median (interquartile range)
placebo pravastatin fosinopril combination
IMT baseline 0.75 (0.64-0.86) 0.73 (0.64-0.88) 0.73 (0.66-0.84) 0.74(0.67-0.88)
IMT after 4 
year
0.81 (0.68-0.93) 0.80 (0.68-0.93) 0.78 (0.68-0.89) 0.77 (0.69-0.92)
Delta IMT 0.05 (-0.05-
0.16)
0.05 (-0.04-
0.13)
0.03 (-0.05-
0.11)
0.05 (-0.04-
0.13)
